University of Leicester
Browse
U487900.pdf (16.5 MB)

Comparative pre-clinical evaluation of resveratrol and 3,4,5,4'-tetramethoxystilbene (DMU212) as colorectal cancer chemopreventive agents

Download (16.5 MB)
thesis
posted on 2014-12-15, 10:34 authored by Stewart Sale
Recently a variety of analogues of resveratrol have been synthesised and investigated in in vivo assays. One analogue, 3,4,5,4'-tetramethoxystilbene (DMU212), showed preferential growth-inhibitory and pro-apoptotic properties in transformed cells, when compared with their untransformed counterparts. Cyclooxygenase enzymes are important mechanistic targets of resveratrol. As part of this study the pharmacokinetic properties of DMU212 were compared with those of resveratrol. Both agents were also compared in terms of abilities to prevent adenoma development in the ApcMin+ mouse, a model of human intestinal carcinogenesis, and to interfere with the expression and activity of COX in human-derived colon cells. Pharmakinetic data showed that resveratrol achieved significantly higher levels than DMU212 systematically, whilst DMU212 exhibited superior availability in the gastrointestinal tract. ApcMin+ mice received either compound with the diet (0.05, 0.2 or 0.5 %), and adenomas were counted after animals were killed. Resveratrol and DMU212 at 0.2 % decreased adenoma load by 27 and 24 % respectively. DMU212 is a better inhibitor of proliferation of human colon cancer cells than resveratrol. Incubation of HCA-7 colon cancer cells for 24-96 h with either compound (1-50 microM) decreased PGE2 production, but only resveratrol decreased COX-2 protein expression. Whilst resveratrol inhibited enzyme activity in purified COX preparations, DMU 212 failed to do so. The results suggest that chemical alteration of the resveratrol molecule to generate DMU212 does not alter its ability to decrease adenoma number in ApcMin+ mice or to interfere with PGE2 generation in cells. However, only resveratrol directly inhibits COX activity and expression.

History

Date of award

2005-01-01

Author affiliation

Cancer Studies and Molecular Medicine

Awarding institution

University of Leicester

Qualification level

  • Doctoral

Qualification name

  • PhD

Language

en

Usage metrics

    University of Leicester Theses

    Categories

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC